NYSE
$13.24▲ 0.19%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $11.03BShares out 8.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
33- 1d agoRegular26.10.24 03:436-KKey event#●●●#●●●
DR REDDYS LABORATORIES LTD
Dr. Reddy's Laboratories announced its financial results for the quarter and half-year ended September 30, 2026. The company reported Q2 consolidated revenue of 86.708 billion INR, a 1.5% decrease year-over-year, with a net profit of 9.25 billion INR. While performance was impacted by lower lenalidomide sales in North America, the company noted continued double-digit growth in its core business segments.…more
$13.24+0.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 1d agoRegular26.10.24 03:156-KKey event
DR REDDYS LABORATORIES LTD
Dr. Reddy's Laboratories has appointed Akhil Ravi as Head of API and Services and a member of the Senior Management Personnel, effective November 13, 2026. Mr. Ravi will continue to serve as the CEO of the company's wholly owned subsidiary, Aurigene Pharmaceutical Services Ltd., and will join the company's Management Council.…more
$13.24+0.19%vs prev closeView filingShare - 1d agoRegular26.10.24 03:026-KKey event
DR REDDYS LABORATORIES LTD
Dr. Reddy's Laboratories filed a Form 6-K with the SEC on October 23, 2026, regarding information previously submitted to stock exchanges in India. This filing serves as a routine disclosure of corporate information and does not contain any material financial changes or significant events.…more
$13.24+0.19%vs prev closeView filingShare
32 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoPre-market26.10.23 21:27Bullish#●●●
Dr. Reddy's Laboratories Q2 Earnings and Revenue Miss Estimates
Dr. Reddy's Laboratories reported Q2 EPS and revenue that fell short of analyst expectations. Both metrics showed a decline compared to the same period last year, indicating weakened financial performance.…more
$13.24+0.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoPre-market26.10.23 18:58
●●●●●●●● ●●●●● ●●●●●●
Dr. Reddy's has introduced new generic versions of Ozempic to capitalize on current supply shortages. This move aims to capture market share while competitors face distribution challenges.…more
$13.24+0.19%vs prev closeShareBenzinga - 10.8Pre-market26.10.08 19:33
●●●●●●●● ●●●●● ●●●●●●
The U.S. FDA has completed a pre-approval inspection of Dr. Reddy's FTO-11 manufacturing facility located in Pydibhimavaram. This inspection is a key regulatory step that supports the company's path toward future product approvals and manufacturing operations.…more
$13.24+0.19%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report